Wall Street

The nation's largest biotech company in terms of market capitalization blew past Wall Street expectations in its most recent earnings report. Rachel Dornhelm has more.

Second quarter earnings reports are expected to be strong, but don't count on Wall Street to react positively. Bob Moon explains why some investors may not be impressed, even though earnings may be impressive.

Commentator Ian Ayres says small shareholders who think their tiny piece of a company leaves them with little voting power could follow the example of <i>recent</i> Greece and use "deliberative polling."

Lawmakers are expected to introduce legislation today to clamp down on the mostly unregulated hedge fund industry. But those hoping for a shorter leash shouldn't hold their breath, Janet Babin reports.

After the dot-com bubble burst, stock analysts shied away from definitive stock ratings like "buy" and "sell." But as Amy Scott reports, one high-profile investment bank has had enough of the ambiguous euphemisms that replaced them.

Newsweek Wall Street editor Allan Sloan and host Scott Jagow take a look at market trends during the first half of the year and where they might be headed.

A major hedge fund is being investigated by the SEC for insider trading, while an SEC rule governing the funds has been thrown out by the courts. Amy Scott reports.

A report out today says the Securities and Exchange Commission is investigating a major US hedge fund for possible insider trading. The investigation is so sensitive that even the SEC's handling of the matter is under review. Janet Babin reports.

New housing starts last month were higher than expected. Those numbers out today brought some relief to the stock market, but investors remain cautious ahead of next week's Fed meeting. Bob Moon reports.

Oil is the most-traded commodity on the planet, but until recently there weren't many good strategies for the average investor who wants a piece of the action. Doesn't mean it's not risky though. Andrew Haeg explains.